No abstract

Whether a mixed type of craniopharyngioma (CP) exists and whether papillary craniopharyngioma (pCP) is on a histopathological continuum with Rathke's cleft cyst (RCC) remain controversial. Herein, we examined the expression and localization of β-catenin, BRAF p.V600E (V600E), and triggering receptor expressed on myeloid cells-1 (TREM-1) in 58 samples including 20 pCPs, 26 adamantinomatous craniopharyngiomas (aCP), and 12 RCCs. Five aCPs were diagnosed with mixed type CPs and the remaining 21 cases were pure aCPs. Four of the 12 RCCs presented with significant squamous epithelium (SE). V600E immunoreactivity was observed in all pCPs in the cytoplasm, but not in the nuclei. aCPs and RCCs, including mixed type CP, did not express V600E. Nuclear β-catenin translocation was detected exclusively in aCPs. TREM-1 was expressed in pCPs. Additionally, TREM-1 expression was detected in the SE of 5 “mixed type” CPs, while it was absent in pure aCPs. TREM-1 was expressed in 4 RCCs with SE, but not in the remaining 8 RCCs. TREM-1 mRNA levels were compared in cultured pCP and aCP cells. TREM-1 mRNA level was significantly (p < 0.001; up to 4.045 fold) higher in pCPs than in aCPs. Western blotting revealed a significantly (p < 0.001; up to 7.19 fold) lower level of TREM-1 expression in aCP cells compared to that in pCP cells. Our findings further supported that RCC and pCP may represent two ends of a morphological spectrum. A variant showing overlapping histological features of aCP and pCP should not be considered as a mixed type.

No abstract

BackgroundWe aimed to develop a risk score to improve the prediction of severe obesity in pediatric craniopharyngiomas (PCs).MethodsOverall, 612 consecutive PCs were prospectively enrolled from six hospitals. Data from 404 participants were analyzed. Participants from three of the six hospitals (n=290) were used to develop a risk score. External validation of the developed risk score was conducted using the participants from the other three hospitals (n=114). Sequential logistic regression was used to develop and validate the risk score. The c statistic and a calibration plot were used to assess the discrimination and calibration of the proposed risk score.ResultsThe overall frequency of severe obesity was 16.1% (65/404). The risk score employed a scale of 0-16 and demonstrated good discriminative power, with an optimism-corrected c statistic of 0.820. Similar results were obtained from external validation, with a c statistic of 0.821. The risk score showed good calibration, with no apparent over- or under-prediction observed in the calibration plots.ConclusionsThis novel risk score is a simple tool that can help clinicians assess the risk of severe obesity in PCs, thereby helping to plan and initiate the most appropriate disease management for these patients in time.

BackgroundBronchial asthma (asthma) is a chronic inflammatory disease of the airways, involving a variety of cells and cellular components, that manifests clinically as recurrent episodes of wheezing, shortness of breath, with or without chest tightness or cough, airway hyperresponsiveness, and variable airflow limitation. The number of people with asthma has reached 358 million worldwide and asthma causes huge economic loss. However, there is a subset of patients who are not sensitive to existing drugs and the existing drugs have many adverse effects. Therefore, it’s important to find new drugs for asthma patients.MethodsPublications related to biologics in asthma published from 2000 to 2022 were retrieved from Web of Science Core Collection. The search strategies were as follows: topic: TS=(biologic* OR “biologic* product*” OR “biologic* therap*” OR biotherapy* OR “biologic* agent*” OR Benralizumab OR “MEDI-563” OR Fasenra OR “BIW-8405” OR Dupilumab OR SAR231893 OR “SAR-231893” OR Dupixent OR REGN668 OR “REGN-668” OR Mepolizumab OR Bosatria OR “SB-240563” OR SB240563 OR Nucala OR Omalizumab OR Xolair OR Reslizumab OR “SCH-55700” OR SCH55700 OR “CEP-38072” OR CEP38072 OR Cinqair OR “DCP-835” OR DCP835 OR Tezspire OR “tezepelumab-ekko” OR “AMG-157” OR tezspire OR “MEDI-9929” OR “MEDI-19929” OR MEDI9929 OR Itepekimab OR “REGN-3500”OR REGN3500 OR “SAR-440340”OR SAR440340 OR Tralokinumab OR “CAT-354” OR Anrukinzumab OR “IMA-638” OR Lebrikizumab OR “RO-5490255”OR “RG-3637”OR “TNX-650”OR “MILR1444A”OR “MILR-1444A”OR”PRO301444”OR “PRO-301444”OR Pitrakinra OR altrakincept OR “AMG-317”OR”AMG317” OR Etokimab OR Pascolizumab OR “IMA-026”OR Enokizumab OR “MEDI-528”OR “7F3COM-2H2” OR 7F3COM2H2 OR Brodalumab OR “KHK-4827” OR “KHK4827”OR “AMG-827”OR Siliq OR Ligelizumab OR “QGE-031” OR QGE031 OR Quilizumab OR Talizumab OR “TNX-901” OR TNX901 OR Infliximab OR Etanercept OR “PRS-060”) AND TS=asthma*. The document type was set to articles and review articles and the language restriction was set to English. Three different analysis tools including one online platform, VOS viewer1.6.18, and CiteSpace V 6.1.R1 software were used to conduct this bibliometric study.ResultsThis bibliometric study included 1,267 English papers published in 244 journals from 2,012 institutions in 69 countries/regions. Omalizumab, benralizumab, mepolizumab, and tezepelumab in relation to asthma were the research hotspots in the field.ConclusionThis study systematically uncovers a holistic picture of existing literature related to the biologic treatment of asthma over the past 20 years. We consulted scholars in order to understand key information in this field from the perspective of bibliometrics, which we believe may greatly facilitate future research in this field.